Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$11.15 +9.5%	$10.88	$3.52 ▼ $23.40	$509.30M	0.84	1.97 million shs	2.64 million shs
KROS Keros Therapeutics	$13.49 -0.1%	$14.08	$9.12 ▼ $72.37	$547.90M	1.31	864,144 shs	1.57 million shs
OPNT Opiant Pharmaceuticals		$20.58	$7.34 ▼ $29.25	$108.83M	0.84	77,920 shs	562,700 shs
VERV Verve Therapeutics	$11.30 +0.4%	$6.16	$2.86 ▼ $11.41	$1.01B	1.67	2.42 million shs	4.14 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	+9.53%	+34.99%	+4.69%	-3.04%	+140.82%
KROS Keros Therapeutics	-0.15%	0.00%	-7.86%	+25.02%	-70.38%
OPNT Opiant Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
VERV Verve Therapeutics	+0.36%	+2.17%	+166.51%	+116.48%	+125.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CAPR Capricor Therapeutics	3.2179 of 5 stars	4.6	3.0	0.0	0.0	1.8	0.8	0.6
KROS Keros Therapeutics	4.104 of 5 stars	4.3	3.0	0.0	0.0	2.7	5.0	0.6
OPNT Opiant Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	3.7292 of 5 stars	4.2	4.0	0.0	0.0	3.0	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPR Capricor Therapeutics	3.13	Buy	$33.75	202.69% Upside
KROS Keros Therapeutics	2.50	Moderate Buy	$30.56	126.51% Upside
OPNT Opiant Pharmaceuticals	0.00	N/A	N/A	N/A
VERV Verve Therapeutics	2.33	Hold	$14.57	28.95% Upside

Current Analyst Ratings Breakdown

Latest OPNT, CAPR, KROS, and VERV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$20.00 ➝ $13.50
6/26/2025	CAPR Capricor Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
6/26/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/25/2025	CAPR Capricor Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/25/2025	CAPR Capricor Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $29.00
6/24/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$77.00
6/23/2025	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$43.00 ➝ $22.00
6/18/2025	VERV Verve Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$28.00 ➝ $11.00
6/18/2025	VERV Verve Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00
6/18/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$13.50
6/17/2025	CAPR Capricor Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPR Capricor Therapeutics	$22.27M	22.87	N/A	N/A	$3.20 per share	3.48
KROS Keros Therapeutics	$3.55M	154.36	N/A	N/A	$14.11 per share	0.96
OPNT Opiant Pharmaceuticals	$47.78M	0.00	N/A	24.75	$9.92 per share	0.00
VERV Verve Therapeutics	$32.33M	31.16	N/A	N/A	$5.83 per share	1.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPR Capricor Therapeutics	-$40.47M	-$1.42	N/A	N/A	N/A	-181.71%	-62.42%	-48.36%	8/6/2025 (Estimated)
KROS Keros Therapeutics	-$187.35M	-$0.18	N/A	N/A	N/A	1.96%	0.75%	0.69%	8/6/2025 (Estimated)
OPNT Opiant Pharmaceuticals	$3.01M	-$6.56	N/A	N/A	N/A	-147.90%	-97.03%	-59.66%	N/A
VERV Verve Therapeutics	-$198.71M	-$2.11	N/A	N/A	N/A	-303.64%	-35.81%	-27.57%	8/14/2025 (Estimated)

Latest OPNT, CAPR, KROS, and VERV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	VERV Verve Therapeutics	-$0.71	-$0.35	+$0.36	-$0.35	$7.13 million	$32.98 million
5/13/2025	Q1 2025	CAPR Capricor Therapeutics	-$0.33	-$0.53	-$0.20	-$0.53	$3.16 million	$2.73 million
5/6/2025	Q1 2025	KROS Keros Therapeutics	-$0.01	$3.62	+$3.63	$3.62	$84.62 million	$211.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
OPNT Opiant Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAPR Capricor Therapeutics	N/A	6.55	6.55
KROS Keros Therapeutics	N/A	19.29	19.29
OPNT Opiant Pharmaceuticals	0.60	5.48	5.48
VERV Verve Therapeutics	N/A	9.84	9.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CAPR Capricor Therapeutics	21.68%
KROS Keros Therapeutics	71.56%
OPNT Opiant Pharmaceuticals	42.39%
VERV Verve Therapeutics	97.11%

Insider Ownership

Company	Insider Ownership
CAPR Capricor Therapeutics	10.50%
KROS Keros Therapeutics	20.60%
OPNT Opiant Pharmaceuticals	25.15%
VERV Verve Therapeutics	19.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPR Capricor Therapeutics	N/A	45.68 million	40.88 million	Optionable
KROS Keros Therapeutics	100	40.62 million	32.25 million	Optionable
OPNT Opiant Pharmaceuticals	37	5.27 million	3.87 million	Not Optionable
VERV Verve Therapeutics	110	89.14 million	71.40 million	Optionable

OPNT, CAPR, KROS, and VERV Headlines

Recent News About These Companies

BMO Capital Markets Downgrades Verve Therapeutics (NASDAQ:VERV) to Hold

June 28 at 8:04 AM | marketbeat.com

Verve Therapeutics' (VERV) Market Perform Rating Reiterated at BMO Capital Markets

June 28 at 2:35 AM | americanbankingnews.com

BMO Capital Markets Reiterates Market Perform Rating for Verve Therapeutics (NASDAQ:VERV)

June 27 at 1:39 PM | marketbeat.com

VERV Verve Therapeutics, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Eli Lilly's Strategic Acquisition of Verve Therapeutics

June 24, 2025 | pharmiweb.comP

GAMMA Investing LLC Acquires 27,485 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

June 24, 2025 | marketbeat.com

Lilly To Acquire Verve For One-Time Cardiovascular Treatments

June 23, 2025 | insidermonkey.com

Research Analysts Offer Predictions for VERV Q2 Earnings

June 21, 2025 | americanbankingnews.com

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

June 20, 2025 | fool.com

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)

June 20, 2025 | globenewswire.com

Lifesci Capital Downgrades Verve Therapeutics (NASDAQ:VERV) to Hold

June 20, 2025 | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Rating Lowered to "Neutral" at HC Wainwright

June 20, 2025 | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Downgraded to "Hold" Rating by Jefferies Financial Group

June 20, 2025 | americanbankingnews.com

Q2 Earnings Forecast for VERV Issued By Lifesci Capital

June 19, 2025 | marketbeat.com

Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug

June 19, 2025 | insidenova.comI

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B

June 19, 2025 | msn.com

Verve Therapeutics (NASDAQ:VERV) Lowered to Hold Rating by William Blair

June 19, 2025 | americanbankingnews.com

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

June 18, 2025 | businesswire.com

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

June 18, 2025 | zacks.com

Verve Therapeutics (NASDAQ:VERV) Receives Neutral Rating from HC Wainwright

June 18, 2025 | marketbeat.com

Lifesci Capital Reaffirms "Market Perform" Rating for Verve Therapeutics (NASDAQ:VERV)

June 18, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPNT, CAPR, KROS, and VERV Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

$11.15 +0.97 (+9.53%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$11.16 +0.00 (+0.04%)

As of 06/27/2025 07:59 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Keros Therapeutics NASDAQ:KROS

$13.49 -0.02 (-0.15%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$13.48 -0.01 (-0.07%)

As of 06/27/2025 05:12 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Opiant Pharmaceuticals NASDAQ:OPNT

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Verve Therapeutics NASDAQ:VERV

$11.30 +0.04 (+0.36%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$11.26 -0.04 (-0.39%)

As of 06/27/2025 07:57 PM Eastern

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time